Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia
RATIONALE: Studying samples fo tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in tissue samples from patients with acute promyelocytic leukemia.
|Leukemia||Genetic: protein expression analysis Genetic: western blotting Other: flow cytometry Other: laboratory biomarker analysis|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Regulation of S100A10 by the PML-RAR-alpha Oncoprotein|
- Demonstration that S100A10 is expressed on acute promyelocytic leukemia cells and that levels of S100A10 correspond to the amount of fibrinolytic activity
- Evaluation of the impact of all-trans retinoic acid (ATRA) on S100A10 level and fibrinolytic activity in vitro
- Evaluation of the impact of S100A10 knockdown on fibrinolytic activity
- Correlation of in vitro findings in cell culture to primary patient samples both pre- and post-ATRA therapy
Biospecimen Retention: Samples With DNA
|Study Start Date:||November 2010|
|Study Completion Date:||February 2011|
|Primary Completion Date:||February 2011 (Final data collection date for primary outcome measure)|
- Demonstrate that S100A10 is expressed on APL cells and that levels of S100A10 correspond to the amount of fibrinolytic activity.
- Evaluate the impact of ATRA on S100A10 level and fibrinolytic activity in vitro.
- Evaluate the impact of S100A10 knockdown on fibrinolytic activity.
- Correlate in vitro findings in cell culture to primary patient samples both pre- and post-ATRA therapy.
OUTLINE: This is a multicenter study.
Previously collected samples are analyzed via flow cytometry and western blot analysis. Cell surface levels of S100A10 and annexin A2 are correlated to the promyelocyte population and total protein levels are examined to determine total annexin A2 and S100A10 in acute promyelocytic leukemia cells.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01232855
|Principal Investigator:||Jason N. Berman, MD||IWK Health Centre|